Latest news from the FASST trial

Jun 8, 2016 | FASST, Projects, Study

inventivaAs mentioned earlier, the FASST trial is a phase 2 clinical trial sponsored by Inventiva Pharma.

The purpose of this study is to evaluate the effectiveness and safety of IVA337 for the treatment of Diffuse Cutaneous Systemic Sclerosis.

Read latest newsletter on the research: FASST Newsletter, May2016


FESCA news & eventsnews & events

This is Living!

This is Living!

FESCA is proud to be a partner of a the new This is Living campaign launched last month by Boehringer Ingelheim.

Share This